In Argentina, senile Osteoporosis is managed by geriatricss. Senile osteoporosis is the age-related form of low bone mass and microarchitectural deterioration that affects adults over 70, driven by long-standing calcium and vitamin D deficiency, reduced osteoblast activity, and secondary hyperparathyroidism rather than the rapid postmenopausal estrogen loss seen in younger women. Roughly 25-30% of women and 6-10% of men over age 75 in the United States meet WHO densitometric criteria for osteoporosis (T-score at or below -2.5 at hip or spine), with one in two women and one in five men over 50 expected to sustain a fragility fracture in their remaining lifetime.
Senile osteoporosis (ICD-10: M81.0 in age-related variant), also called Type II osteoporosis, is a systemic skeletal disorder of adults over 70 characterized by decreased bone mass, deterioration of trabecular and cortical microarchitecture, and increased fracture risk. Unlike Type I postmenopausal osteoporosis, which preferentially erodes trabecular bone in the first 5-10 years after menopause, senile osteoporosis affects both cortical and trabecular bone, develops slowly over decades, and reflects cumulative defects in calcium absorption, renal vitamin D 1-alpha-hydroxylation, sex-hormone production in both sexes, growth-hormone and IGF-1 signaling, and osteoblast number and function. Secondary hyperparathyroidism driven by reduced serum 1,25-dihydroxyvitamin D and falling dietary calcium accelerates bone resorption. The condition affects both axial and appendicular skeleton, producing the classic triad of femoral neck, vertebral, and distal radius fractures.
The key symptoms of Senile Osteoporosis are: No symptoms until fracture occurs in 60-70% of patients; the disease is therefore called a silent epidemic and is diagnosed by densitometry or after a first fragility fracture., Sudden severe mid-thoracic or lumbar back pain after bending, lifting, or even coughing, indicating a new vertebral compression fracture; pain typically peaks for 4-6 weeks then settles into chronic ache., Loss of height of 2 cm or more over a year, or cumulative loss of 4 cm or more from young-adult height, signals multiple vertebral fractures., Progressive thoracic kyphosis (dowager's hump) with forward head posture, restrictive chest wall changes, and a protuberant abdomen as anterior vertebral bodies collapse., Hip pain, groin pain, or inability to bear weight after a fall from standing height — most commonly femoral neck or intertrochanteric fracture., Wrist pain and deformity (dinner-fork) after a fall on an outstretched hand — distal radius (Colles) fracture is often the first sentinel event in late middle age., Chronic mid-back ache, fatigue, and reduced exercise tolerance from kyphosis-related restrictive lung disease and altered abdominal mechanics..
Diagnosis combines clinical risk assessment with bone densitometry. The starting point in adults age 70+ is a fracture history and a FRAX or Garvan calculator to estimate 10-year major osteoporotic and hip fracture probabilities. Dual-energy X-ray absorptiometry (DEXA) of the lumbar spine, femoral neck, and total hip remains the WHO standard: a T-score at or below -2.5 at any site defines osteoporosis, between -1.0 and -2.5 is osteopenia, and -1.0 or above is normal. A T-score above -2.5 plus a fragility fracture also qualifies as clinical osteoporosis and mandates treatment. Vertebral fracture assessment (VFA) by DEXA or thoracolumbar lateral radiograph identifies asymptomatic vertebral fractures, which are present in roughly 15-25% of patients age 70+ and not always reported as back pain. Laboratory work-up rules out secondary causes: complete blood count, calcium, phosphate, magnesium, 25-hydroxyvitamin D, parathyroid hormone, thyroid-stimulating hormone, creatinine and estimated GFR, serum protein electrophoresis and free light chains (to exclude myeloma), testosterone in men, 24-hour urinary calcium, and tissue transglutaneous IgA in selected patients. Bone-turnover markers (CTX, P1NP) help monitor treatment response in selected patients. Trabecular bone score (TBS) on lumbar DEXA, quantitative CT, and high-resolution peripheral CT add micro-architectural information in research and complex cases.
Outcomes depend on age at diagnosis, BMD severity, fracture history, comorbidities, and adherence to therapy. Patients with osteoporosis treated for 3-5 years with bisphosphonates achieve 30-50% reductions in hip and vertebral fracture risk and roughly 5-7% gain in lumbar BMD. Patients who sustain a hip fracture face a 1-year mortality of 20-30% (40% in men) and only 30-50% recover their pre-fracture level of independent walking; one in four requires long-term institutional care. Vertebral fractures carry a 5-year mortality of 15-20% and a 5-fold risk of a second vertebral fracture within 1 year if untreated. Anabolic therapy followed by an antiresorptive (treat-to-target strategy) raises BMD into the osteopenic range within 18-24 months in roughly 50% of severe patients. Mortality benefit is documented for zoledronic acid initiated after hip fracture (HORIZON-RFT: 28% reduction at 1.9 years) and is plausible for denosumab and oral bisphosphonates in elders with high comorbidity.
Refer to a geriatrician, endocrinologist, or rheumatologist when fractures occur on therapy, when secondary causes are suspected (unexplained hypercalcemia, abnormal protein electrophoresis, very-young-age low BMD), when severe T-scores below -3.0 require anabolic therapy, or when complex polypharmacy and frailty complicate management. Patients with hip fracture should be enrolled in a fracture liaison service for systematic post-fracture bone-protective treatment.
Find specialists →BMD response to bisphosphonates is detectable on DEXA at 12-24 months; anabolic agents produce visible spine BMD gains within 6-12 months. Bone-turnover markers (CTX, P1NP) fall by 30-70% within 3 months of effective anti-resorptive therapy. Acute vertebral fracture pain settles in 4-12 weeks; chronic kyphosis-related pain may persist. Functional recovery after hip fracture: 40-60% of patients return to pre-fracture walking by 6 months; full recovery extends to 12 months in best cases.
Combine progressive resistance training (2-3 sessions/week working all major muscle groups at 60-80% of one-repetition maximum), weight-bearing aerobic activity (30 minutes most days such as brisk walking or stair climbing), and balance/proprioceptive work (tai chi, single-leg stance with support, heel-to-toe walking). Patients with vertebral fractures should avoid heavy forward-flexion exercises (sit-ups, toe-touches) and instead emphasize spine-extension exercises (prone press-ups, scapular retraction). Supervised programs delivered by a physiotherapist trained in osteoporosis achieve the largest BMD and fall-prevention gains.
Choose a clinician affiliated with a fracture liaison service or osteoporosis clinic. Ask whether they routinely use FRAX, perform vertebral fracture assessment, prescribe parenteral therapy (zoledronate, denosumab, romosozumab), and coordinate with falls and rehabilitation teams. Continuity over years matters because bisphosphonate drug holidays and post-denosumab transitions require ongoing oversight.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Argentina.
Apply as specialist →Specialists who treat Senile Osteoporosis. Get expert guidance and personalized care.